Background and Objectives: Insulin-like growth factor-1 (IGF-1) levels have been investigated in rheumatoid arthritis (RA), however, produced inconsistent results. The purpose of this meta-analysis was to derive a more precise conclusion about serum/plasma IGF-1 levels in RA patients.
Methods: PubMed, Embase and the Cochrane Library databases were searched up to December 2018 in English, and the studies comparing serum/plasma IGF-1 levels between RA group and healthy control group were what we are interested in. The Newcastle-Ottawa Scale (NOS) was used to assess the methodological quality of the included studies. The heterogeneity test was performed by the Cochrane Q statistic and I2 –statistic. The publication bias was evaluated by the funnel plot and Egger’s test. The standard mean difference (SMD) with 95% confidence interval (CI) was calculated by the fixed-effects or random-effects model.
Results: A total of eleven articles with 334 cases and 261 controls were finally included. Compared with the healthy group, the RA group had lower circulating IGF-1 levels (pooled SMD= -0.936, 95% CI= -1.382 to -0.489, p<0.001). The subgroup analysis showed that RA patients from Asia (SMD= -0.645, 95% CI= -1.063 to -0.228, p= 0.002) and Europe (SMD= -1.131, 95% CI= -1.767 to -0.495, p<0.001) had lower circulating IGF-1 levels, no significant difference in plasma/serum IGF-1 levels was observed in RA patients from America. Sensitivity analysis indicated the stability and credibility of the overall effect sizes.
Conclusion: Patients with RA have lower circulating IGF-1 level than healthy controls, particularly for patients from Asia and Europe. Further studies are necessary to elucidate the role of IGF-1 in the pathological process of RA.
[http://dx.doi.org/10.1097/01.bor.0000160780.13012.be] [PMID: 15838240]
[http://dx.doi.org/10.1007/BF02331388] [PMID: 9015706]
[http://dx.doi.org/10.1002/art.1780370215] [PMID: 7510486]
[http://dx.doi.org/10.1016/j.freeradbiomed.2018.08.038] [PMID: 30176344]
[http://dx.doi.org/10.1002/1529-0131(199804)41:4<634:AID-ART10>3.0.CO;2-1] [PMID: 9550472]
[http://dx.doi.org/10.1385/ENDO:19:3:287] [PMID: 12624428]
[http://dx.doi.org/10.3899/jrheum.150280] [PMID: 26329340]
[http://dx.doi.org/10.1177/0961203313502860] [PMID: 23989734]
[http://dx.doi.org/10.1016/j.semarthrit.2005.03.001] [PMID: 16084221]
[http://dx.doi.org/10.1080/03009740802055984] [PMID: 18666027]
[http://dx.doi.org/10.1002/art.1780400218] [PMID: 9041945]
[http://dx.doi.org/10.1093/rheumatology/keh421] [PMID: 15466894]
[http://dx.doi.org/10.1046/j.1365-2567.2002.01525.x] [PMID: 12460191]